Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Tomonari Sasaki Last modified date:2019.10.28

Associate Professor / Department of Health Sciences, Division of Quantum Radiation Sciences
Department of Health Sciences
Faculty of Medical Sciences


Graduate School
Undergraduate School
Other Organization
Administration Post
Other


Academic Degree
M.D., Ph.D.
Field of Specialization
Radiation Oncology
Research
Research Interests
  • Research on change of applicator position and dose distribution before and after treatment in image-guided brachytherapy for cervical cancer
    keyword : cervical cancer, image-guided brachytherapy, dose distribution
    2017.06~2019.05.
  • Verification of feasibility and safety of definitive radiotherapy for patients with prostate cancer using TomoDirect by Tomotherpay
    keyword : Tomotherapy, prostate cancer , TomoDirect
    2017.06~2019.05.
  • Research for anatomical position of point B in patients with uterine cervical cancer who treated with radiation therapy
    keyword : Uterine cervical cancer, brachytherapy, point B
    2016.06~2019.03.
  • Quality assurance of total body irradiation by Tomotherapy using TomoDirect method
    keyword : Total body irradiation, Tomotherapy
    2016.05~2019.03.
  • Development of Chemoradiotherapy for patients with locally advanced non-small lung cancer
    keyword : non-small cell lung cancer, chemoradiotherapy
    2010.08~2016.08.
  • Research for radical radiation therapy for patients with recurrent esophageal cancer after radical radiation therapy
    keyword : esophageal cancer, recurrence, radiation therapy
    2012.05~2015.04.
  • Clinical results of radiotherapy for patient with prostate cancer after surgery, in adjuvant or slavage setting
    keyword : postoperative radiotherapy adjuvant salvage
    2012.01~2013.04.
  • Efficacy and feasibility of chemoradiotherapy for patients with local advanced lung cancer.
    keyword : lung cancer, chemoradiotherapy, surgery
    2011.04~2012.11.
Current and Past Project
  • This trial is phase I study for patients with stage I-II non-small cell lung cancer, who treated with stereotactic radiotherapy concurrently with oral administration of TS-1.
  • This trial is randomized phase III trial for patients with c-N2 stage IIIb resectable non-small cell lung cancer. The standard treatment arm of those population is definitive chemoradiotherapy, and trial arm is preoperative chemoradiotherapy followed by surgery.
Academic Activities
Papers
1. Ichinose Y, Seto T, Sasaki T, Yamanaka T, Okamoto I, Takeda K, Tanaka M, Katakami N, Sawa T, Kudoh S, Saka H, Nishimura Y, Nakagawa K, Fukuoka M., S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706)., J Thorac Oncol., 6, 12, 2069-75, 2011.12.
2. Shinoto M, Shioyama Y, Sasaki T, Nakamura K, Ohura H, Toh Y, Higaki Y, Yamaguchi T, Ohnishi K, Atsumi K, Hirata H, Honda H. , Clinical results of definitive chemoradiotherapy for patients with synchronous head and neck squamous cell carcinoma and esophageal cancer., Am J Clin Oncol., 34, 4, 362-6, 2011.08.
3. Sasaki T, Nakamura K, Ogawa K, Onishi H, Okamoto A, Koizumi M, Shioyama Y, Mitsumori M, Teshima T; the Japanese Patterns of Care Study Working Subgroup on Prostate Cancer., Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the Patterns of Care Study in Japan., BJU Int, 10.1111/j.1464-410X.2009.08616.x, 104 , 10 , 1462-1466, 2009.11.
4. Sasaki T, Nakamura K, Shioyama Y, Toh Y, Okamura K, Ohura H, Hirata H, Honda H., Treatment outcomes of radiotherapy for patients with stage I esophageal cancer: a single institute experience., Am J Clin Oncol, 10.1097/COC.0b013e31805c1410, 30 , 5 , 514-519, 2007.10.
Presentations
1. 松本和樹, 佐々木智成,笠井裕貴, 福山幸秀, 寺嶋廣美, Dose Evaluation Indices in Myeloablative Total Body Irradiation Using Static Mode of Helical Rotational Intensity Modulated Radiation Therapy System with Different Numbers of Ports, Diponegoro大学・九州大学合同シンポジウム, 2019.03.
2. Educational Lecture: Lung cancer.
3. Dose Evaluation Indices in Myeloablative Total Body Irradiation Using Static Mode of Helical Rotational Intensity Modulated Radiation Therapy System with Different Numbers of Ports.
4. 枝光華奈, 佐々木智成,松川英明, 平山 亮太, 廣瀬 貴章, 福永 淳一, Intra-fractional Dose Variation of Organs at Risk in High Dose Rate Image-guided Brachytherapy for Cervical Cancer, 第75回日本放射線技術学会総会学術大会, 2018.04, Purpose】To evaluate the intra-fractional dose variation of organs at risk (OARs) in high dose rate (HDR) computed tomography (CT)-based brachytherapy (BT) for cervical cancer.
【Method】Twenty-one patients (56 HDR fractions) received CT-based BT for cervical cancer. For all cases, treatment plans (Original Plan) were generated with CT-images (Original CT) after applicator insertion. Additional CT-images (After CT) were acquired immediately after HDR BT fraction. We generated the virtual treatment plans (After Plan) using After CT, and the dose distribution was created with the same source position as that of the Original Plan. In the present study, we investigated the intra-fractional dose variation of OARs (rectum and bladder) by comparing the dose volume histogram (DVH) parameters (D2cc, D1cc, and D0.1cc) between the Original Plan and After Plan. Furthermore, we analyzed whether the intra-fractional dose variation has a correlation with the intra-fractional volume variation of OARs or the time from planning to irradiation.
【Result】The dose differences (mean ± SD) of D2cc, D1cc, and D0.1cc for rectum were -0.03 ± 0.50, -0.06 ± 0.57, and -0.19 ± 0.81 Gy, and for bladder were 1.06 ± 0.99, 1.23 ± 1.22, and 1.66 ± 1.95 Gy, respectively. No statistically significant difference was observed for rectum; however, a significant difference was seen in all DVH parameters for bladder (p < 0.05). The volume variation of OARs had a significant correlation with the dose variation of all DVH parameters for rectum and bladder. On the other hand, no significant correlation was found between the dose variation of all DVH parameters and the time from planning to irradiation.
【Conclusion】In the CT-based BT, the dose distribution at the planning stage can be different from the dose distribution after irradiation. Intra-fractional volume variation of OARs affects the dose distribution; however, the time from planning to irradiation does not affect the dose variation.
(1938 characters)

【Clinical relevance/application】The dose distribution of OARs differs between the planning stage and application, which may affect treatment outcomes and adverse events..
5. Anatomical and DVH analyses of Point B in brachytherapy for uterine cervical cancer.
6. 佐々木智成, Progress of clinical research on the combination of radiotherapy and targeted therapy for lung cancer, 第13回日本臨床腫瘍学会学術集会, 2015.07.
7. Tomonari Sasaki, Katsumasa Nakamura, Saiji Ohga, Tadamasa Yoshitake, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Hideki Hirata, Hiroshi Honda, Clinical results of stereotactic radiotherapy for patients with choroidal melanoma using CyberKnife® ( Accuray Inc., Sunnyvale, California) system , ESTRO33, 2014.04.
8. Tomonari Sasaki, Katsumasa Nakamura, Yoshiyuki Shioyama, Saiji Ohga, Tadamasa Yoshitake, Makoto Shonoto, Kotaro Terashima, Kaori Asai, Keiji Matsumoto, Hideki Hirata, Hiroshi Honda, Clinical results of salvage radiation therapy after radical prostatectomy for patients with prostate cancer, RSNA2013, 2013.12.
9. Object: To investigate the therapeutic effectiveness of preoperative chemoradiotherapy with TS-1 which is composed of tegafur (5-FU prodrug), 5-chloro-2, 4-dihydroxypyridine (CDHP: inhibitor dihydroxy pyrimidine dehydroxygenase) and potassium oxonate (inhibitor of phosphoribosyl transferase) plus ciplatin, followed by surgery in patients with locally advanced non-small cell lung cancer.
Material and Methods; From 2005 to 2010, 42 patients staged IIb-IV (UICC 1997) have been treated with concomitant chemoradiotherapy, followed by surgery. Patients characteristics are as follows; male/female= 35/7, median age: 61 years (range: 42-77), clinical stage IIb/IIIa/IIIb/IV= 2/23/14/3, Histology: squamous cell carcinoma/adenocarcinoma/large cell carcinoma/others=11/3/21/7. Three patients had distant metastases (brain or adrenal glands) which were well controlled by surgery or gamma knife treatment. Chemotherapy consisted of cisplatin (60 mg/m² on day 1) and TS-1 (orally at 40 mg/m²/dose b.i.d., on days 1-14) repeated every 3 weeks for 2 cycles. Beginning on day 1, radiotherapy was started and delivered to the primary tumor and hilar and /or mediastinal lymph nodes. Total dose was 40-60 Gy (median: 40Gy) with conventional fraction size 2 Gy. The median treatment period of chemoradiotherapy was 29 days, and the median interval between end of chemoradiotherapy and surgery was 27 days. Twenty-eight patients received adjuvant chemotherapy after surgery..
10. Object: To investigate the therapeutic effectiveness of preoperative chemoradiotherapy with TS-1 which is composed of tegafur (5-FU prodrug), 5-chloro-2, 4-dihydroxypyridine (CDHP: inhibitor dihydroxy pyrimidine dehydroxygenase) and potassium oxonate (inhibitor of phosphoribosyl transferase) plus ciplatin, followed by surgery in patients with locally advanced non-small cell lung cancer.
Material and Methods; From 2005 to 2010, 42 patients staged IIb-IV (UICC 1997) have been treated with concomitant chemoradiotherapy, followed by surgery. Patients characteristics are as follows; male/female= 35/7, median age: 61 years (range: 42-77), clinical stage IIb/IIIa/IIIb/IV= 2/23/14/3, Histology: squamous cell carcinoma/adenocarcinoma/large cell carcinoma/others=11/3/21/7. Three patients had distant metastases (brain or adrenal glands) which were well controlled by surgery or gamma knife treatment. Chemotherapy consisted of cisplatin (60 mg/m² on day 1) and TS-1 (orally at 40 mg/m²/dose b.i.d., on days 1-14) repeated every 3 weeks for 2 cycles. Beginning on day 1, radiotherapy was started and delivered to the primary tumor and hilar and /or mediastinal lymph nodes. Total dose was 40-60 Gy (median: 40Gy) with conventional fraction size 2 Gy. The median treatment period of chemoradiotherapy was 29 days, and the median interval between end of chemoradiotherapy and surgery was 27 days. Twenty-eight patients received adjuvant chemotherapy after surgery.
.
Membership in Academic Society
  • International Association for the Study of Lung Cancer
  • Japan Radiological Society
  • Japanese Society for Therapeutic Radiology and Oncology
Educational
Educational Activities
Principal education for students of Department of Health Sciences
Clinical education for students of Department of Health Sciences
Research training for graduate students of Department of Health Sciences